Applications of Herbal Medicine to Treat Autosomal Dominant Polycystic Kidney Disease

Shao, Guangying; Zhu, Shuai; Yang, Baoxue

doi:10.3389/fphar.2021.629848

Cited by 4 publications

(6 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Перебіг захворювання визначає множинне утворення кіст в обох нирках. Кісти походять, як правило, з тубулярного уроепітелію [8,9]. При збереженій рШКФ (за рахунок компенсаторної гіперфільтрації) середній загальний об'єм нирок за рік збільшується, як правило, на 5 % та у 3 рази перевищує нормальний об'єм нирок (ранній автосомно-домінантний полікістоз нирок) [9, 10].…”

Section: полікістоз нирокunclassified

“…При збереженій рШКФ (за рахунок компенсаторної гіперфільтрації) середній загальний об'єм нирок за рік збільшується, як правило, на 5 % та у 3 рази перевищує нормальний об'єм нирок (ранній автосомно-домінантний полікістоз нирок) [9, 10]. Збільшення кіст у розмірі чинить компресію на інтактну ниркову паренхіму, унаслідок чого порушуються функції та нормальна структура нирки [8], включно із судинами та канальцями, що викликає запалення з переходом в інтерстиціальний фіброз [9]. При PKD 1 мутації пацієнти досягають термінальної стадії ниркової недостатності в більшості випадків у віці 54 роки, а при PKD 2 -74 роки [9].…”

Section: полікістоз нирокunclassified

“…При порушенні комплексу PC 1 -PC 2 клітинна передача сигналів Ca 2+ припиняється, унаслідок чого збільшується внутрішньоклітинний циклічний аденозинмонофосфат (цАМФ) і активується шлях передачі сигналів протеїнкінази А (PKA). Такі сигнальні шляхи, як mTOR (mammalian target of rapamycin), JAK (Janusкіназа), Wnt (об'єднання двох генів-ортологів: гена wingless (wg) плодових мушок дрозофіл і протоонкогена мишей -int-1) і MAPK (mitogen-activated protein kinase), активуються, а інші шляхи пригнічуються, наприклад шлях AMPK (аденозинмонофосфатактивована протеїнкіназа), що відповідає за внутрішньоклітинний синтез енергії [8].…”

Section: полікістоз нирокunclassified

See 2 more Smart Citations

The effect of antioxidant therapy on the course of predialysis chronic kidney disease in a patient with comorbidity

Denova

2023

KIDNEYS

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is almost always associated with comorbidities such as diabetes, hyperuricemia/gout, urolithiasis, often with urinary tract infection, hypertension, polycystic kidney disease, and other conditions. Autosomal dominant polycystic kidney disease is an inherited kidney disease (1/1000–1/400 worldwide) affecting mainly adults, caused predominantly by mutations in PKD1 (85–90 % of cases) and PKD2 genes (10–15 % of cases), which encode polycystin-1 and polycystin-2 proteins, respectively. In adults with preserved kidney function, the prevalence of gout increases from 1 to 2 % (hyperuricemia up to 11 %), in patients with CKD stage 4 — up to 32 % (hyperuricemia up to 80 %). 70 % of patients with gout and 50 % of patients with hyperuricemia have stage 2 CKD. CKD contributes to a decrease in the urinary excretion of uric acid. In patients with CKD, hyperuricemia is considered to be a serum uric acid level > 6 mg/dL in women and > 7 mg/dL in men. Hyperuricemia is very often observed in hypertension and type 2 diabetes. In patients with kidney disease, diabetes is a major factor of mortality and morbidity. Diabetic nephropathy can be suspected in a patient with type 2 diabetes in the presence of albuminuria and/or diabetic retinopathy. Signs of diabetic nephropathy: basement membrane thickening, mesangial expansion, and increased vascular permeability to albumin induced by nonenzymatic glycation of collagen and laminin. Comorbidity has a negative impact on patients’ health due to increased morbidity and mortality. Such patients are at risk of rapid progression of CKD into the end stage, which requires renal replacement therapy. Therefore, early diagnosis, treatment and prevention of CKD complications are important for such patients. This article highlights the impact of antioxidant therapy and phytoneering on the course of CKD in patients with comorbidities.

show abstract

Section: полікістоз нирокunclassified

See 1 more Smart Citation

The effect of antioxidant therapy on the course of predialysis chronic kidney disease in a patient with comorbidity

Denova

2023

KIDNEYS

View full text Add to dashboard Cite

show abstract

“…It pursues an overall therapeutic effect with a multi-ingredient treatment in the form of combination drug formulas in an attempt to improve therapeutic efficacy and lower drug side-effects and could also be an effective approach of reducing drug resistance ( Jiang, 2005 ). Therefore, the studies of TCMs have attracted attention owing to its superiority in the treatment of refractory diseases ( Chen et al, 2016b ; Li et al, 2021a ; Shao G. et al, 2021 ; Wang Y. W. et al, 2021 ; Yang and Wu, 2021 ). A variety of compounds isolated from natural products have been protected against renal fibrosis ( Feng et al, 2019b ; Luo et al, 2021 ; Shao M. et al, 2021 ; Zhao et al, 2011 ; Zhou F. et al, 2021 ).…”

Section: Natural Products As An Alternative Therapy Against Tubuloint...mentioning

confidence: 99%

TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis

Sun

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) was a major public health problem worldwide. Renal fibrosis, especially tubulointerstitial fibrosis, is final manifestation of CKD. Many studies have demonstrated that TGF-β/Smad signaling pathway plays a crucial role in renal fibrosis. Therefore, targeted inhibition of TGF-β/Smad signaling pathway can be used as a potential therapeutic measure for tubulointerstitial fibrosis. At present, a variety of targeting TGF-β1 and its downstream Smad proteins have attracted attention. Natural products used as potential therapeutic strategies for tubulointerstitial fibrosis have the characteristics of acting on multiple targets by multiple components and few side effects. With the continuous research and technique development, more and more molecular mechanisms of natural products have been revealed, and there are many natural products that inhibited tubulointerstitial fibrosis via TGF-β/Smad signaling pathway. This review summarized the role of TGF-β/Smad signaling pathway in tubulointerstitial fibrosis and natural products against tubulointerstitial fibrosis by targeting TGF-β/Smad signaling pathway. Additionally, many challenges and opportunities are presented for inhibiting renal fibrosis in the future.

show abstract

“…Cordyceps sinensis ( C. sinensis ) and Cordyceps militaris ( C. militaris ) are two well-known Cordyceps species. For many years, C. sinensis was used to treat fatigue, renal and pulmonary dysfunction, hyperglycemia, hyperlipidemia, and arrhythmia [ 23 ], and its effects in CKD patients and kidney transplant recipients have been studied [ 24 – 26 ]. Generally, C. militaris is relatively amenable to mass production [ 27 ] and exhibits both diverse and specific pharmacological properties [ 28 – 30 ].…”

Section: Introductionmentioning

confidence: 99%

Improvement in the Blood Urea Nitrogen and Serum Creatinine Using New Cultivation of Cordyceps militaris

Yang

Kuo

Wang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Chronic kidney disease (CKD) is a critical public health issue with a huge financial burden for both patients and society worldwide. Unfortunately, there are currently no efficacious therapies to prevent or delay the progression of end-stage renal disease (ESRD). Traditional Chinese medicine practices have shown that Cordyceps militaris (C. militaris) mycelia have a variety of pharmacologically useful properties, including antitumor, immunomodulation, and hepatoprotection. However, the effect of mycelial C. militaris on CKD remains unclear. Methods. Here, we investigated the effects of C. militaris mycelia on mice with CKD using four types of media: HKS, HKS with vitamin A (HKS + A), CM, and CM with vitamin A (CM + A). Results. The results at day 10 revealed that the levels of blood urea nitrogen (BUN) were significantly lower in the HKS (41%), HKS + A (41%), and CM + A (34%) groups compared with those in the corresponding control groups (nephrectomic mice). The level of serum creatinine in the HKS + A group decreased by 35% at day 10, whereas the levels in the HKS and CM + A groups decreased only by 14% and 13%, respectively, on day 30. Taken together, this is the first report using four new media (HKS, HKS + A, CM, and CM + A medium) for C. militaris mycelia. Each medium of mycelial C. militaris on CKD exhibits specific effect on BUN, serum creatinine, body weight, total protein, and uric acid. Conclusions. Taken together, this is the first report using four new media (HKS, HKS + A, CM, and CM + A medium) for C. militaris mycelia. Each medium of mycelial C. militaris on CKD exhibits specific effects on BUN, serum creatinine, body weight, total protein, and uric acid. We concluded that treatment with C. militaris mycelia cultured in HKS or CM + A medium could potentially prevent the deterioration of kidney function in mice with CKD.

show abstract

Applications of Herbal Medicine to Treat Autosomal Dominant Polycystic Kidney Disease

Cited by 4 publications

References 61 publications

The effect of antioxidant therapy on the course of predialysis chronic kidney disease in a patient with comorbidity

The effect of antioxidant therapy on the course of predialysis chronic kidney disease in a patient with comorbidity

TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis

Improvement in the Blood Urea Nitrogen and Serum Creatinine Using New Cultivation of Cordyceps militaris

Contact Info

Product

Resources

About